Link
Évaluation de la pertinence d’utiliser le vaccin pneumococcique conjugué 13 valent plutôt que 10-valent dans une perspective économique au Québec (English Version)I
Organization: Quebec National Institute of Public HealthPublished: 2019
"Au Québec, le vaccin pneumococcique conjugué 10-valent (VPC-10) a remplacé le vaccin 13-valent (VPC-13) au cours de l’année 2018 pour l’immunisation des enfants ayant un risque d’infection invasive à pneumocoque faible ou modéré. Le plus faible coût du VPC-10 a été un élément important dans la décision." - Évaluation de la pertinence d’utiliser le vaccin pneumococcique conjugué 13 valent plutôt que 10-valent dans une perspective économique au Québec
Resource Group:
Evidence
Product Type: Report
Immunization Policies
Cost Effectiveness
Vaccine Preventable Diseases
Communicable Diseases
Pneumococcal Disease
Product Type: Report
Category:
Policy,Immunization Policies,Cost Effectiveness,Vaccine Preventable Diseases,Communicable Diseases,Pneumococcal Disease PolicyImmunization Policies
Cost Effectiveness
Vaccine Preventable Diseases
Communicable Diseases
Pneumococcal Disease
Language:
French
PDFResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.